Study of ORL-1F (L-fucose) in Patients With Leukocyte Adhesion Deficiency Type II
Overview
Study of ORL-1F in Patients With Leukocyte Adhesion Deficiency Type II
Study Type
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: November 1, 2018
Interventions
- Drug: L-fucose
- Oral ORL-1F
Arms, Groups and Cohorts
- Other: Treatment with ORL-1F – L-fucose
Clinical Trial Outcome Measures
Primary Measures
- Decrease in infection frequency
- Time Frame: 12 months after treatment started
- Statistically significant decrease in infection frequency
Secondary Measures
- Decrease in neutrophil count
- Time Frame: 30 days after treatment started
- Statistically significant decrease in absolute neutrophil count
Participating in This Clinical Trial
Inclusion Criteria
- Diagnosis of Leukocyte Adhesion Deficiency Type II. – Less than 18 years old. Exclusion Criteria:
- Diagnosis of any other disease that is not a manifestation of Leukocyte Adhesion Deficiency Type II.
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: 18 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Orpha Labs
- Provider of Information About this Clinical Study
- Sponsor
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.